Citadel Advisors’s Metagenomi Therapeutics MGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$52.2K Buy
49,266
+31,415
+176% +$37.8K ﹤0.01% 13346
2026
Q2
$21.2K Buy
17,851
+858
+5% +$1.15K ﹤0.01% 13394
2026
Q1
$22.8K Sell
16,993
-161,179
-90% -$250K ﹤0.01% 12640
2025
Q4
$289K Buy
+178,172
New +$386K ﹤0.01% 10231
2025
Q3
– Sell
-60,624
Closed -$89.7K – 14343
2025
Q2
$89.7K Buy
+60,624
New +$94.9K ﹤0.01% 11417
2025
Q1
– Sell
-149,698
Closed -$540K – 15739
2024
Q4
$540K Sell
149,698
-654,764
-81% -$1.58M ﹤0.01% 8380
2024
Q3
$1.75M Buy
804,462
+74,610
+10% +$259K ﹤0.01% 5795
2024
Q2
$2.93M Buy
729,852
+5,951
+0.8% +$40.9K ﹤0.01% 4598
2024
Q1
$7.52M Buy
+723,901
New +$8.32M ﹤0.01% 3338

Other funds holding MGX

Citadel Advisors's MGX Position: Q3 2026 in Review

Citadel Advisors increased its Metagenomi Therapeutics (MGX) stake by 176% in Q3 2026, buying an estimated $37.8K and bringing the position to 49,266 shares worth $52.2K. The position accounts for ﹤0.01% of the portfolio, ranked #13346.

Citadel Advisors first reported a position in MGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $7.52M in Q1 2024. 44 funds tracked by Wall St. Rank hold MGX as of Q3 2026.

  • Citadel Advisors held 49,266 shares of Metagenomi Therapeutics worth $52.2K as of Q3 2026.
  • Citadel Advisors bought 31,415 Metagenomi Therapeutics shares in Q3 2026, an estimated $37.8K.
  • Metagenomi Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #13346 holding.
  • Citadel Advisors first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Citadel Advisors's Metagenomi Therapeutics position peaked at $7.52M in Q1 2024.
  • 44 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.